Literature DB >> 6358414

Prolyl endopeptidase: inhibition in vivo by N-benzyloxycarbonyl-prolyl-prolinal.

T C Friedman, M Orlowski, S Wilk.   

Abstract

The activity of prolyl endopeptidase in homogenates of mouse tissues was determined 30 min after intraperitoneal injection of N-benzyloxycarbonyl-prolyl-prolinal (1.25 mg/kg), a potent transition state analog inhibitor (K1 = 14 nM) of prolyl endopeptidase (EC 3.4.21.26). A more than 85% decrease of enzyme activity was obtained in all tissues. The in vivo degradation of potential prolyl endopeptidase substrates was studied by following the release of sulfamethoxazole from N-benzyloxycarbonylglycyl-prolyl-sulfamethoxazole, a model synthetic substrate of the enzyme. When this substrate was given intraperitoneally, its enzymatic degradation was blocked after administration of the inhibitor in a dose- and time-dependent manner, indicating inhibition of the enzyme in vivo. Of interest is the long duration of the inhibition. After a relatively low inhibitor dose (5 mg/kg) significant inhibition was seen in most tissues even after 6 h. The brain was particularly sensitive to the effect of the inhibitor. Since prolyl endopeptidase readily degrades many proline-containing neuropeptides, the inhibitor should be of value in studies on the role of the enzyme in neuropeptide metabolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6358414     DOI: 10.1111/j.1471-4159.1984.tb09723.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal.

Authors:  A V Bakker; S Jung; R W Spencer; F J Vinick; W S Faraci
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

2.  Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite.

Authors:  Peter L Bonate; David Beyerlein; Jennifer Crawford; Stephanie Roth; Roy Krumbholz; Steve Schmid
Journal:  AAPS J       Date:  2007-12-14       Impact factor: 4.009

3.  Prolyl endopeptidase contributes to early neutrophilic inflammation in acute myocardial transplant rejection.

Authors:  Gregory A Payne; Nirmal S Sharma; Charitharth V Lal; Chunyan Song; Lingling Guo; Camilla Margaroli; Liliana Viera; Siva Kumar; Jindong Li; Dongqi Xing; Melanie Bosley; Xin Xu; J Michael Wells; James F George; Jose Tallaj; Massoud Leesar; J Edwin Blalock; Amit Gaggar
Journal:  JCI Insight       Date:  2021-03-22

4.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.